Product Description
AFNT-111 is a T-cell therapy being developed by AffiniT Therapeutics to target and treat cancers with a KRAS G12V mutation. (Sourced from: https://affinittx.com/wp-content/uploads/Affini-T_Non-Confidential_Deck_Jefferies_June-2022.pdf)
Mechanisms of Action: Cell Therapy
Novel Mechanism: No
Modality: Cell Therapy
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AffiniT Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Pancreatic Cancer|Colorectal Cancer|Adenocarcinoma|Non-Small-Cell Lung Cancer
Phase 0: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| RG1123135 | P1 |
Active, not recruiting |
Non-Small-Cell Lung Cancer|Pancreatic Cancer|Adenocarcinoma|Colorectal Cancer |
2025-12-31 |